Early outcomes, associated factors and predictive values of clinical outcomes of tandospirone in generalized anxiety disorder: a post-hoc analysis of a randomized, controlled, multicenter clinical trial

References

• Huang YQ, Wang Y, Wang H, et al. Prevalence of mental disorders in China:a cross-sectional epidemiological study. Lancet Psychiatry. 2019;6(3):211–224.
   PubMed Web of Science ®Google Scholar
• Gelder M, Mayou R, Cowen P, et al. Oxford psychiatry [M]. 4th ed. China: Sichuan University Press; 2001.
   Google Scholar
• Wittchen HU.Generalized anxiety disorder: prevalence, burden, and cost to society. Depress Anxiety. 2002;16(4):162–171.
   PubMed Web of Science ®Google Scholar
• DeMartini J, Patel G, Fancher TL. Generalized anxiety disorder. Ann Intern Med. 2019;170(7):ITC49–ITC64.
   PubMed Web of Science ®Google Scholar
• Kujanpää TS, Jokelainen J, Auvinen JP, et al. The association of generalized anxiety disorder and somatic symptoms with frequent attendance to health care services: a cross-sectional study from the Northern Finland Birth Cohort 1966. Int J Psychiatry Med. 2017;52(2):147–159.
   PubMed Web of Science ®Google Scholar
• Baoyan Z. Current status and progress in the pharmacological treatment of generalized anxiety disorder. Elect J Clin Med Lit. 2015;(28):5964–5965.
   Google Scholar
• Wu WY, Zhang MY, Fang YR, et al. 5-HT1A receptor partial agonists and anxiety disorders: clinical application of 5-HT1A receptor clinical application progress of partial agonists. Chin J Psych. 2016;49(5):344–346.
   Google Scholar
• Huang X, Yang J, Yang S, et al. Role of tandospirone, a 5-HT1A receptor partial agonist, in the treatment of Central nervous system disorders and the underlying mechanisms. Oncotarget. 2017; 78(60):102705–102720.
   Google Scholar
• Chinese medicine and health culture association, psychosomatic medicine research branch, expert recommendations on the clinical application of tandospirone in the treatment of patients with anxiety states in general hospitals. China Med. 2019;6(14):935–939.
   Google Scholar
• Katzman MA, Bleau P, Blier P, et al. Canadian clinical practice guidelines for the management of anxiety, posttranmatic stress and obsessive compulsive disorders. BMC Psychiatry. 2014;14(Suppl 1):S1．
   PubMed Web of Science ®Google Scholar
• Locke AB, Kirst N, Shuhz CG, et al. Diagnosis and management of generalized anxiety disorder and panic disorder in adults. Am Fam Physician. 2015;9l(9):617–624.
   Google Scholar
• Bejuela HR, Osser DN. The psychopharmacology algorithm project at the Harvard South shore program: an algorithm for generalized anxiety disorder. Harv Rev Psychiatry. 2016;24(4):243–256.
   PubMed Web of Science ®Google Scholar
• Lin J, Su Y, Wang C, et al. Effects of tandospirone augmentation in major depressive disorder patients with high anxiety: a multicenter, randomized, parallel-controlled, openlabel study. J Psychiatr Res. 2018;99:104–110.
   PubMed Web of Science ®Google Scholar
• Chen H, Lin Q, Lin T, et al. A controlled study of the efficacy and safety of tandospirone combined with escitalopram in the treatment of vascular depression: a pilot randomized controlled trial at a single-center in China. J Psychiatr Res. 2019;114:133–140.
   PubMed Web of Science ®Google Scholar
• Gao Q, Li CX, Yang YL, et al. SSRIs combined with different doses of tandospirone in the treatment of depression with anxiety efficacy and safety. Chongqing Med. 2018;47(32):4126–4129.
   Google Scholar
• Hengartner MP, Davies J, Read J. Antidepressant withdrawal – the tide is finally turning. Epidemiol Psychiatr Sci. 2019;29:e52.
   PubMed Web of Science ®Google Scholar
• Lam RW. The importance of early symptom relief in antidepressant treatment: focus on agomelatine. J Psychopharmacol. 2010;24(2 Suppl):27–30.
   PubMedGoogle Scholar
• Machado-Vieira R, Salvadore G, Luckenbaugh DA, et al. Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder. J Clin Psychiatry. 2008;69(6):946–958.
   PubMed Web of Science ®Google Scholar
• Nishitsuji K, To H, Murakami Y, et al. Tandospirone in the treatment of generalised anxiety disorder and mixed anxiety-depression: results of a comparatively high dosage trial. Clin Drug Investig. 2004;24(2):121–126.
   PubMed Web of Science ®Google Scholar
• Yang ZZ. Controlled observation of high-dose versus low-dose tandospirone in the treatment of generalized anxiety. Chinese Foreign Med. 2010;29(29):131.
   Google Scholar
• Li Q, Zhang H, Lin G, et al. Relative safety and efficacy of two doses of tandospirone citrate for generalized anxiety disorder: a multicenter randomized controlled trial. Neuropsychiatr Dis Treat. 2022;18:1653–1664.
   PubMed Web of Science ®Google Scholar
• Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50–55.
   PubMed Web of Science ®Google Scholar
• Guy W. 1976. ECDEU assessment manual for psychopharmacology, revised. Rockville, MD: National Institute of Mental Health.
   Google Scholar
• Ware J, Jr,Kosinski M, Keller SD. 12-Item ShortForm health survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34(3):220–233.
   PubMed Web of Science ®Google Scholar
• Szegedi A, Jansen WT, van Willigenburg APP, et al. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. J Clin Psychiatry. 2009;70(3):344–353.
   PubMed Web of Science ®Google Scholar
• Kim J-M, Kim S-Y, Stewart R, et al. Improvement within 2 weeks and later treatment outcomes in patients with depressive disorders: the CRESCEND study. J Affect Disord. 2011;129(1–3):183–190.
   PubMed Web of Science ®Google Scholar
• Shan S, Nan C, Yongzhu H. Advances in the pharmacological treatment of generalized anxiety disorder.J Trans Med. 2016;3(3):51–54.
   Google Scholar
• Qian M, Shen Z, Lin M, et al. Early improvement predicts 8‐week treatment outcome in patients with generalized anxiety disorder treated with escitalopram or venlafaxine. Asia Pac Psychiatry. 2017;9(4). DOI:10.1111/appy.12270
   Web of Science ®Google Scholar
• Katzman MA, Nierenberg AA, Wajsbrot DB, et al. Speed of improvement in symptoms of depression with desvenlafaxine 50 mg and 100 mg compared with placebo in patients with major depressive disorder. J Clin Psychopharmacol. 2017;37(5):555–561.
   PubMed Web of Science ®Google Scholar
• Yuan J, Li XT, Liu Y, et al. Research progress on the onset of action of antidepressant drugs[J]. Neurological Disorders and Mental Health. 2020;20(8):561–566.
   Google Scholar
• Jisheng H, Jinping D, Yantong X. Advances in the research of fast-acting antidepressants[J]. Chinese Journal of New Drugs. 2015;24(23):2669–2676.
   Google Scholar
• Lam RW. Onset, time course and trajectories of improvement with antidepressants. Eur Neuropsychopharmacol. 2012;22(Suppl3):S492–S498.
   PubMedGoogle Scholar
• Tadic A, Helmreich I, Mergl R, et al. Early improvement is a predictor of treatment outcome in patients with mild major, minor or subsyndromal depression. J Affect Disord. 2010;120(1–3):86–93.
   PubMed Web of Science ®Google Scholar
• Vermeiden M, Kamperman AM, Vulink ME, et al. Early improvement as a predictor of eventual antidepressant treatment response in severely depressed inpatients. Psychopharmacology (Berl). 2015;232(8):1347–1356.
   PubMed Web of Science ®Google Scholar
• Kudlow PA, Cha DS, McIntyre RS. Predicting treatment response in major depressive disorder: the impact of early symptomatic improvement. Can J Psychiatry. 2012;57(12):782–788.
   PubMed Web of Science ®Google Scholar
• Pollack A MH, Kornstein B SG, Spann C ME, et al. Early improvement during duloxetine treatment of generalized anxiety disorder predicts response and remission at endpoint. J Psychiatr Res. 2008;42(14):1176–1184.
   PubMed Web of Science ®Google Scholar
• Allen TA, Lam RW, Milev R, et al. Early change in reward and punishment sensitivity as a predictor of response to antidepressant treatment for major depressive disorder: a CAN-BIND-1 report. Psychol Med. 2019;49(10):1629–1639.
   Google Scholar
• Nelson JC, Portera L, Leon AC. Are there differences in the symptoms that respond to a selective serotonin or norepinephrine reuptake inhibitor? Biol Psychiatry. 2005;57(12):1535–1542.
   PubMed Web of Science ®Google Scholar
• Yang WC, Lin CH, Wang FC, et al. Factors related to the improvement in quality of life for depressed inpatients treated with fluoxetine. BMC Psychiatry. 2017;17(1):309.
   PubMedGoogle Scholar
• Ninan PT. Dissolving the burden of generalized anxiety disorder. J Clin Psyc. 2001;62(Suppl. 19):5–10.
   Google Scholar